中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report

文献类型：期刊论文

作者Fu, Meng2,3,4; Feng, Chun-Mei1; Xia, Da-Qing3; Ji, Zi-Mei3; Xia, Huai-Ling3; Hu, Na-Na3; Leng, Zai-Jun3; Xie, Wang3; Fang, Yuan3; Cao, Le-Jie3
刊名FRONTIERS IN ONCOLOGY
出版日期2022-08-16
卷号12
关键词savolitinib MET exon 14 skipping neoadjuvant therapy non-small cell lung cancer targeted therapy
ISSN号2234-943X
DOI10.3389/fonc.2022.954886
通讯作者Cao, Le-Jie(sycaolejie@163.com) ; Zhang, Jun-Qiang(yany1980@126.com)
英文摘要MET exon 14 skipping mutation (METex14m) is rare and occurs in approximately 1-4% of all non-small cell lung cancer (NSCLC) patients and approximately 2.8% of resected stage I-III NSCLC patients. Savolitinib is an oral, potent and highly selective type Ib MET inhibitor, which has been shown to be promising activity and acceptable safety profile in patients with advanced NSCLC harboring METex14m. Most recently, many studies have been probing into the feasibility and efficacy of target therapy for perioperative application in NSCLC. Interestingly, there are very few recorded cases of such treatments. Here, we presented that systemic treatment with the MET inhibitor savolitinib before surgery could provide the potential to prolong overall survival (OS) of patients with locally advanced potentially resectable NSCLC. A 49-year-old woman was diagnosed with stage IIIA (T2bN2M0) primary lung adenocarcinoma exhibiting a METex14m by real-time quantitative polymerase chain reaction (RT-qPCR). Given that the tumor load and the size of lymph nodes experienced a significant downstaging after the neoadjuvant treatment of savolitinib with 600mg once a day for 5 weeks, left lower lobectomy and systemic lymphadenectomy were successfully performed. The pathological response was 50% and the final postoperative pathological staging was pT1cN0M0, IA3 (AJCC, 8(th) edition). The case provides empirical basis for the neoadjuvant treatment with savolitinib in METex14m-positive locally advanced primary lung adenocarcinoma, which will offer some innovative insights and clinical evidence for more effective clinical treatment of neoadjuvant targeted therapy for METex14m-positive NSCLC.
资助项目Anhui Provincial Key Clinical Specialty Discipline Construction Program ; [2021szdzk05]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000847866300001
出版者FRONTIERS MEDIA SA
资助机构Anhui Provincial Key Clinical Specialty Discipline Construction Program
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/131804]  
专题中国科学院合肥物质科学研究院
通讯作者Cao, Le-Jie; Zhang, Jun-Qiang
作者单位1.Anhui Med Univ, Hefei, Peoples R China
2.Univ Sci & Technol China, Hefei, Peoples R China
3.Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Resp & Crit Care Med, Div Life Sci & Med, Hefei, Peoples R China
4.Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Hefei, Peoples R China
推荐引用方式
GB/T 7714		 Fu, Meng,Feng, Chun-Mei,Xia, Da-Qing,et al. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report[J]. FRONTIERS IN ONCOLOGY,2022,12.
APA Fu, Meng.,Feng, Chun-Mei.,Xia, Da-Qing.,Ji, Zi-Mei.,Xia, Huai-Ling.,...&Zhang, Jun-Qiang.(2022).Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report.FRONTIERS IN ONCOLOGY,12.
MLA Fu, Meng,et al."Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report".FRONTIERS IN ONCOLOGY 12(2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。